NetworkNewsBreaks – TC Biopharm PLC (NASDAQ: TCBP) Closes on $17.5M Public Offering
TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced that it has closed on a previously announced initial public offering. The offering comprised more than 4 million American Depositary Shares ("ADSs”) as well as warrants to purchase up to 8,235,296 ADSs. According to the announcement, underwriters have partially exercised their option and purchased an additional 1,235,294 warrants; those warrants were purchased at an exercise price of $4.25 per warrant. TCBP will receive gross proceeds of some $17.5 million from the offering, prior to standard deductions. TC Biopharm plans to use monies from the offering…







